vascuCAP vs Cardiomo
AI Verdict
Choose vascuCAP if…
Choose vascuCAP (now ElucidVivo/PlaqueIQ) if your clinical practice requires precise, non-invasive quantification of atherosclerotic plaque composition from CT angiography. This tool is ideal for optimizing treatment decisions and stratifying cardiovascular risk by providing histologically-validated characterization of plaque, including lipid-rich necrotic core and intraplaque hemorrhage. It's particularly well-suited for radiologists, cardiologists, and vascular surgeons seeking detailed 3D visualizations and AI-enabled analysis to predict stroke and heart attack risk.
View vascuCAP →Choose Cardiomo if…
Choose Cardiomo if you need a continuous, remote heart health monitoring solution for patients, especially those in geriatrics or with known cardiovascular conditions. This medical-grade wearable device and AI-powered platform are best for detecting cardiovascular diseases like arrhythmias and providing real-time alerts to users, caregivers, and healthcare providers. It's suitable for long-term monitoring of vital signs such as ECG, heart rate, and respiration, offering features like fall detection and mobile app integration for ongoing patient oversight.
View Cardiomo →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CardiomoCardiomo, with its wearable patch and mobile app, appears to offer a more straightforward and accessible user experience for continuous remote monitoring. vascuCAP, while providing advanced 3D visualization, is a diagnostic imaging analysis tool used by clinicians, suggesting a more complex interface and workflow. Cardiomo's focus on real-time alerts and a user-friendly app for patients and caregivers also points to higher usability for its target audience.
Clinical Value
vascuCAPvascuCAP demonstrates strong clinical value through its FDA clearance and histologically-validated plaque quantification, which has been shown to be more accurate in predicting stroke than traditional methods. Cardiomo, while offering continuous monitoring and early alerts, is still undergoing FDA approval and its clinical validation studies, though promising, are generally smaller scale.
Pricing & Value
TieBoth tools require contacting the company for current pricing, making a direct comparison difficult. While Cardiomo previously offered a device with a subscription, current pricing is not publicly available. vascuCAP operates on a usage-based model, with estimated costs per analysis, which can introduce budget uncertainty. Without transparent pricing for either, it's challenging to definitively determine which offers better value.
Enterprise Readiness
vascuCAPvascuCAP offers both cloud and on-premise deployment options and integrates with DICOM and PACS/EMR systems, indicating a strong readiness for enterprise-level healthcare environments. Cardiomo's cloud-based platform with a mobile app is suitable for remote patient monitoring, but its enterprise readiness for large-scale hospital system integration is less explicitly detailed.
Innovation
vascuCAPvascuCAP's innovation lies in its histologically-validated AI for non-invasive CT angiography analysis, quantifying specific plaque components like lipid-rich necrotic core and intraplaque hemorrhage, which were previously difficult to obtain non-invasively. This provides unique insights for personalized treatment decisions. Cardiomo's continuous, AI-powered remote monitoring with a wearable patch is innovative for patient engagement and early detection, but vascuCAP's diagnostic precision based on histological validation represents a more fundamental advancement in imaging interpretation.
Support & Docs
TieNeither the provided structured facts nor the web search results offer specific details regarding the depth or accessibility of support and documentation for either vascuCAP or Cardiomo. Therefore, it is not possible to pick a winner in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | vascuCAP | Cardiomo |
|---|---|---|
| Name | vascuCAP (now ElucidVivo/PlaqueIQ) | Cardiomo |
| Company | Elucid Bioimaging | Cardiomo, Inc. |
| Description | FDA-cleared AI software for non-invasive CT angiography analysis, quantifying plaque composition and assessing cardiovascular risk to optimize treatment decisions. | Medical-grade wearable device and an AI-powered platform for continuous and remote heart health monitoring, designed to detect cardiovascular diseases and provide timely alerts to users and caregivers. |
| Key Features | AI-enabled CT angiogram analysis, Histologically-validated plaque quantification and characterization, 3D visualization of arterial vessels and plaque, Risk stratification for stroke and heart attack, Support for personalized treatment decisions, Quantification of lipid-rich necrotic core, calcification, non-calcified matrix, intraplaque hemorrhage, DICOM integration and PACS/EMR interoperability, Cloud and on-premise secure deployment options | Medical-grade wearable patch, Continuous vital sign monitoring (ECG, heart rate, respiration, skin temperature), AI-powered disease detection (arrhythmias, cardiovascular events), Real-time alerts and notifications, Mobile application (Android and iOS), HIPAA-compliant cloud analytics, Fall detection, Long battery life (up to 7-10 days) |
| Categories | Cardiology AI, Clinical Decision Support & Reference | Cardiology AI, Wearables & Remote Monitoring (RPM) |
| Specialties | Cardiology, Radiology, Vascular Surgery | Cardiology, Geriatrics, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring vascuCAP and Cardiomo.